Investing in a New Year and a New Era of Medicine

Hello, and we hope your 2024 is off to a great start!?

Many people's New Year's resolutions often revolve around health, so we thought it might be interesting to kick off our first newsletter of the year with more on the life science tools industry.? You might not hear about this sector every day, but there are some big advancements taking place that could not only benefit the industry but also society as a whole!??

Shivani Vohra , portfolio manager of the Parnassus Investments Growth Equity Fund, shares more on approvals in multi-billion dollar markets, including diabetes and obesity treatments, antibody drug conjugates for cancer, and amyloid plaque-clearing antibodies for Alzheimer’s.?

“These new modalities or breakthroughs have resulted in the number of FDA approvals doubling over the last decade vs. the 2000s, and what’s even more exciting to me is that the approvals for novel targets, not just ‘me too’ drugs have more than doubled. For example, in 2009 the FDA approved three novel therapies, and in 2020 they approved ten,” Vohra told Asset TV.?

“This really is a step-level change and a new era in medicine,” adds Vohra. “As an investor, I’m excited about the profits this unlocks, the companies that will benefit, but also just as a person it’s truly incredible to look at this pace of innovation and see three times the number of approvals for brand new therapies and targets and that’s three times the number of diseases that we can treat and potentially cure.”

Thanks for reading and wishing you health, wealth, and happiness in the year ahead!

For a deeper dive into this topic check out:

- WisdomTree: 2024 Outlook - Volatility, Rates & the Fed

- Fixed Income Rallies to Avoid Third Negative Year

- Looking Ahead to 2024

- General outlook: Q1 2024 Capital Markets Perspective

- Navigating the Shifting Landscape of the Health Care Tools Industry